(NASDAQ: MNOV) Medicinova's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.
Medicinova's earnings in 2026 is -$12,010,330.On average, 3 Wall Street analysts forecast MNOV's earnings for 2026 to be -$19,010,325, with the lowest MNOV earnings forecast at -$18,264,822, and the highest MNOV earnings forecast at -$19,569,452. On average, 3 Wall Street analysts forecast MNOV's earnings for 2027 to be -$20,010,868, with the lowest MNOV earnings forecast at -$19,226,128, and the highest MNOV earnings forecast at -$20,599,423.
In 2028, MNOV is forecast to generate -$22,011,955 in earnings, with the lowest earnings forecast at -$21,148,741 and the highest earnings forecast at -$22,659,366.